Receive The Newest Study Notifications

MELBOURNE, Australia--(Business Wire)--Regenerative medicine company Exopharm Limited (ASX:EX1) announces first dosing has occurred in the PLEXOVAL Phase I study using exosomes isolated from human platelets for wound healing, Exopharm’s first human clinical trial....

CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced it has completed Cohort 1 enrollment with no dose-limiting...

EDISON, NJ / ACCESSWIRE / January 28, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) ("Hepion" or the "Company"), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic...

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results detailing pharmacokinetics (PK), tolerability, and safety with its lead...

– Submission based on two clinical trials in patients with advanced hepatocellular carcinoma who had received prior systemic therapy – ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda),...

Verastem, Inc. (Nasdaq: VSTM), (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that its partner CSPC...

CAMBRIDGE, Mass., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the U.S. Food and Drug Administration (FDA)...

GI Dynamics ® Inc. (ASX:GID), a medical device company that is developing EndoBarrier ® for patients with type 2 diabetes and obesity, is pleased to announce the first patient in the United States (U.S.) STEP-1 clinical trial has been enrolled at Michigan Medicine in...

INDIANAPOLIS, Jan. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD4, an investigational Phase 3, randomized, placebo-controlled study evaluating the safety and...

Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin NuTide:121 Trials-in-Progress Poster Presented at ASCO-GI SAN FRANCISCO, Jan. 27, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced...

Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for Dravet Syndrome, announced today that the Company successfully completed a Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to assess safety and...

TEL AVIV, Israel and BETHESDA, Maryland, Jan. 27, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that in a series of tests conducted at the...

SAN DIEGO, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced the positive results of multiple resiniferatoxin (RTX) pre-pivotal (phase 1b/2) clinical studies, which will be presented at two upcoming prestigious pain...

NEW YORK, Jan. 27, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders...

- Data Presented at the 2020 ASCO GI Cancers Symposium - CAMBRIDGE, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab,...

Risdiplam (RG7916) Pivotal FIREFISH Study Demonstrated Statistically Significant Improvement in Infants with Type 1 Spinal Muscular Atrophy  - Study meets primary endpoint in patients living with type 1 SMA - - To date, more than 400 patients have been treated with...

NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals, Inc. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it will be presenting preclinical results of TNX-801 in a poster at the 2020 ASM Biothreats...

– Data from the CheckMate 040 trial presented at the 2020 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium – January 24, 2020 07:30 AM Eastern Standard Time ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced phase...

HANGZHOU and SHAOXING, China, Jan. 22, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (Ascletis, 1672.HK) announces today the approval for ASC22 to conduct clinical trials in chronic hepatitis B patients in China from China's National Medical Products Administration. ASC22...

Study meets primary endpoint in patients living with type 1 SMA To date, more than 400 patients have been treated with risdiplam across all studies, with no treatment related safety findings leading to study withdrawal in any risdiplam trial Risdiplam PDUFA expected...